Abstract
Type 2 diabetes mellitus (T2DM) complicated with non-alcoholic fatty liver disease (NAFLD) is difficult to treat. The present study explored the efficacy of (liraglutide) Lira in treating T2DM complicated with NAFLD. A total of 127 patients suffering from T2DM complicated with NAFLD were enrolled in the present study, and randomly assigned to a Lira group (liraglutide injection: 0.6–1.2 mg/day, 12 weeks, n=52) or a Metformin (Met) group (oral metformin: 1000–1500 mg/day, 12 weeks, n=75). During the treatment phase, the values for fasting plasma glucose (FPG), 2 h plasma glucose (2hPG), glycated hemoglobin (HbA1c), aspartate aminotransferase (AST)/alanine aminotransferase (ALT), and adiponectin (APN) decreased in both the Lira and Met groups, and the levels of Δ2hPG, ΔAST/ALT, and ΔAPN in the Lira group were significantly lower than those in the Met group. The values for total cholesterol (TC), triglycerides (TG), low-and high-density lipoproteins (LDL and HDL), ALT, AST, weight, body mass index (BMI), waist to hip ratio (WHR), and C-reactive protein were markedly increased in both groups, and levels of ΔAST, ΔALT, Δweight, ΔBMI, ΔWHR, and ΔCRP (C-reactive protein) in the Lira group were significantly higher than those in the Met group. An analysis of treatment efficacy showed that liraglutide was better than metformin in its ability to significantly decrease the ALT levels in patients with combined T2DM and NAFLD. Furthermore, liraglutide was more effective than metformin at ameliorating the severity of T2DM complicated with NAFLD, and produced its effects by alleviating liver inflammation and improving liver function.
Highlights
Type 2 diabetes mellitus (T2DM) is a common health problem worldwide, and its incidence has increased in recent decades [1]
Patients were selected if they met the following criteria: (i) T2DM was diagnosed in accordance with criteria provided by the American Diabetes Association; i.e. fasting glucose ranged from 7.0–10.0 mmol/l, and glycated hemoglobin (HbA1c) was
The two groups showed no significant differences in values for total cholesterol (TC), TG, low-density lipoprotein (LDL), high-density lipoprotein (HDL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), fasting plasma glucose (FPG), 2 h plasma glucose (2hPG), HbA1c, homeostasis model assessment-insulin resistance index (HOMA-IR), APN, and C-reactive protein (CRP) (P>0.05, Table 1)
Summary
Type 2 diabetes mellitus (T2DM) is a common health problem worldwide, and its incidence has increased in recent decades [1]. 415 million individuals suffered from T2DM in 2015, and this number is predicted to reach 642 million by 2040 [2]. Non-alcoholic fatty liver disease (NAFLD) is a common metabolic disease associated with T2DM, insulin resistance, and other metabolic diseases [3,4]. NAFLD occurs in 70–90% of patents with T2DM, making it an important worldwide public health problem [5,6]. The treatment of T2DM has markedly changed in recent years, the best treatment for T2DM complicated with NAFLD remains unknown [7]. It is important to explore new methods for treating NAFLD in patients with T2DM
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
